In line with studies conducted by our contemporaries, we found that silencing PD-L1 in antigen-presenting dendritic cells (DC) notably enhanced anti-tumor immunity, particularly when combined with DC activators [31,41]. This evidence concerns the gene CD274 and neoplasm.